Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript

Unidentified Analyst: Great, thank you.

Operator: All right, thank you. I am showing no further questions at this time. I would now like to turn it back to Jack Khattar for closing remarks.

Jack Khattar: Thank you. In concluding our call this afternoon, our growth products, Qelbree and GOCOVRI, delivered strong growth of 61% in net sales in the first nine months of this year and far exceeded the loss of Trokendi XR net sales. We will continue to focus on making the 2023 transition as smooth as possible as we move away from the legacy products and set the stage for continued growth in 2024 and beyond. We are well positioned for continued growth with three key areas. First, the existing portfolio that we have today with Qelbree and GOCOVRI, driving significant growth and together with the rest of the portfolio, generating strong cash flow, allowing us to invest in our pipeline. Second, an innovative R&D pipeline of differentiated first-in-class molecules.

And finally, continued execution on the corporate development side to augment our growth through external growth opportunities. Thanks for joining us this afternoon. We look forward to updating you on our next call.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.